BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35409086)

  • 21. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
    Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IDH1
    Kim GH; Choi SY; Oh TI; Kan SY; Kang H; Lee S; Oh T; Ko HM; Lim JH
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours.
    Sun C; Zhao Y; Shi J; Zhang J; Yuan Y; Gu Y; Zhang F; Gao X; Wang C; Wang Y; Wang Z; Hu P; Qin J; Xiao L; Chang T; Wang L; Xi Y; Yin H; Chen H; Zhang L; Cheng G; Lin J; Zhang M; Li Z; Ye J
    J Neurooncol; 2019 Jun; 143(2):187-196. PubMed ID: 31004262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
    Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
    Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
    van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma.
    Fukunaga T; Fujita Y; Kishima H; Yamashita T
    PLoS One; 2018; 13(11):e0206552. PubMed ID: 30388142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The expression of IDH1 (R132H) is positively correlated with cell proliferation and angiogenesis in glioma samples].
    Shi J; Zhao Y; Yuan Y; Wang C; Xie Z; Gao X; Xiao L; Ye J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):360-3. PubMed ID: 26927556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
    Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
    Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extracellular glutamate and IDH1
    Tiburcio PDB; Gillespie DL; Jensen RL; Huang LE
    J Neurooncol; 2020 Feb; 146(3):427-437. PubMed ID: 32020473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive Analysis of
    Guo X; Zhou S; Yang Z; Li ZA; Hu W; Dai L; Liang W; Wang X
    Front Oncol; 2022; 12():896433. PubMed ID: 35646697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
    Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
    Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
    Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
    Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.